Report of the forth asian prostate cancer (a-cap) study meeting

Ji Youl Lee, Tomotaka Taniguchi, Kai Zhang, Chi Fai Ng, Lukman Hakim, Rainy Umbas, Choung Soo Kim, Byungha Chung, Wun Jae Kim, Teng Aik Ong, Jasmine Lim, Hideyuki Akaza

Research output: Contribution to journalArticle

Abstract

The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data updating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.

Original languageEnglish
Pages (from-to)581-586
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume49
Issue number6
DOIs
Publication statusPublished - 2019 May 29

Fingerprint

Prostatic Neoplasms
Jordan
Southeastern Asia
Far East
Tokyo
Malaysia
Thailand
Korea
Turkey
Registries
Japan
Prospective Studies
Seoul
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Youl Lee, J., Taniguchi, T., Zhang, K., Ng, C. F., Hakim, L., Umbas, R., ... Akaza, H. (2019). Report of the forth asian prostate cancer (a-cap) study meeting. Japanese Journal of Clinical Oncology, 49(6), 581-586. https://doi.org/10.1093/jjco/hyz053
Youl Lee, Ji ; Taniguchi, Tomotaka ; Zhang, Kai ; Ng, Chi Fai ; Hakim, Lukman ; Umbas, Rainy ; Kim, Choung Soo ; Chung, Byungha ; Kim, Wun Jae ; Aik Ong, Teng ; Lim, Jasmine ; Akaza, Hideyuki. / Report of the forth asian prostate cancer (a-cap) study meeting. In: Japanese Journal of Clinical Oncology. 2019 ; Vol. 49, No. 6. pp. 581-586.
@article{c749e6214eee48ef9b818959fc6ad9f9,
title = "Report of the forth asian prostate cancer (a-cap) study meeting",
abstract = "The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data updating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.",
author = "{Youl Lee}, Ji and Tomotaka Taniguchi and Kai Zhang and Ng, {Chi Fai} and Lukman Hakim and Rainy Umbas and Kim, {Choung Soo} and Byungha Chung and Kim, {Wun Jae} and {Aik Ong}, Teng and Jasmine Lim and Hideyuki Akaza",
year = "2019",
month = "5",
day = "29",
doi = "10.1093/jjco/hyz053",
language = "English",
volume = "49",
pages = "581--586",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

Youl Lee, J, Taniguchi, T, Zhang, K, Ng, CF, Hakim, L, Umbas, R, Kim, CS, Chung, B, Kim, WJ, Aik Ong, T, Lim, J & Akaza, H 2019, 'Report of the forth asian prostate cancer (a-cap) study meeting', Japanese Journal of Clinical Oncology, vol. 49, no. 6, pp. 581-586. https://doi.org/10.1093/jjco/hyz053

Report of the forth asian prostate cancer (a-cap) study meeting. / Youl Lee, Ji; Taniguchi, Tomotaka; Zhang, Kai; Ng, Chi Fai; Hakim, Lukman; Umbas, Rainy; Kim, Choung Soo; Chung, Byungha; Kim, Wun Jae; Aik Ong, Teng; Lim, Jasmine; Akaza, Hideyuki.

In: Japanese Journal of Clinical Oncology, Vol. 49, No. 6, 29.05.2019, p. 581-586.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Report of the forth asian prostate cancer (a-cap) study meeting

AU - Youl Lee, Ji

AU - Taniguchi, Tomotaka

AU - Zhang, Kai

AU - Ng, Chi Fai

AU - Hakim, Lukman

AU - Umbas, Rainy

AU - Kim, Choung Soo

AU - Chung, Byungha

AU - Kim, Wun Jae

AU - Aik Ong, Teng

AU - Lim, Jasmine

AU - Akaza, Hideyuki

PY - 2019/5/29

Y1 - 2019/5/29

N2 - The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data updating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.

AB - The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data updating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.

UR - http://www.scopus.com/inward/record.url?scp=85067280425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067280425&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz053

DO - 10.1093/jjco/hyz053

M3 - Article

VL - 49

SP - 581

EP - 586

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

ER -

Youl Lee J, Taniguchi T, Zhang K, Ng CF, Hakim L, Umbas R et al. Report of the forth asian prostate cancer (a-cap) study meeting. Japanese Journal of Clinical Oncology. 2019 May 29;49(6):581-586. https://doi.org/10.1093/jjco/hyz053